Clinical Trial Update: Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating mesenchymal stem cells as a treatment for multiple sclerosis, conducted by the University of Cambridge.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: University of Cambridge | Conditions: Multiple Sclerosis | Phase 1, Phase 2 | Status: COMPLETED